Suvratoxumab
Suvratoxumab
Suvratoxumab (pronounced soo-vra-tox-u-mab) is a monoclonal antibody designed for the prevention of Staphylococcus aureus infections. It is currently under development by AstraZeneca and its global biologics research and development arm, MedImmune.
Etymology
The name "Suvratoxumab" is derived from the International Nonproprietary Naming system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while the prefix "Suvra-" does not have a specific meaning and is used for unique identification.
Mechanism of Action
Suvratoxumab works by binding to the lipoteichoic acid (LTA), a component of the cell wall of Staphylococcus aureus. This binding prevents the bacteria from adhering to and invading host cells, thereby preventing infection.
Clinical Trials
Suvratoxumab has undergone Phase 2 clinical trials for the prevention of Staphylococcus aureus ventilator-associated pneumonia (VAP) in mechanically ventilated patients. The results showed a reduction in the incidence of Staphylococcus aureus VAP.
Related Terms
External links
- Medical encyclopedia article on Suvratoxumab
- Wikipedia's article - Suvratoxumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski